返回
Redhill Biopharma Ltd（RDHL）价格
RDHL 股价走势图
RDHL 收益
Redhill Biopharma Ltd
$1.36
3.81%
$0.05
收盘价：Jan 16, 16:00:00 GMT-5
$1.35
-0.02%
$0
盘后：Jan 16, 20:00:00 GMT-5
关键数据
前收盘价
$1.31
开盘价
$1.33
当日区间
$1.26 - $1.39
52周范围
$0.905 - $6.8
交易量
86.7K
平均成交量
1.3M
每股收益（TTM）
-0.00
股息收益率
--
市值
$4.5M
什么是 RDHL？
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.